September 6, 2018 08:48 AM EDTUpdated 09:13 AM

Juno will pay $24M to settle the JCAR015 scandal — but don’t expect that to change industry attitudes on reporting snafus

A notorious string of patient deaths caused by Juno Therapeutics’ JCAR015 wound up killing the one-time CAR-T star, derailing their shot at joining the breakthrough …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

Juno will pay $24M to settle the JCAR015 scandal — but don’t expect that to change industry attitudes on reporting snafus

This article is available only to Premium subscribers

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

Revolution’s KRAS drugs appear competitive in several lung cancer settings

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Juno will pay $24M to set­tle the JCAR015 scan­dal — but don’t ex­pect that to change in­dus­try at­ti­tudes on re­port­ing sna­fus

This article is available only to Premium subscribers

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

Juno will pay $24M to settle the JCAR015 scandal — but don’t expect that to change industry attitudes on reporting snafus

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

Revolution’s KRAS drugs appear competitive in several lung cancer settings

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges